Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603937 | 1.00 | HRH3 (0.49) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL6890619 | 0.86 | S1PR1 (0.54) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL14728368 | 0.86 | S1PR1 (0.54) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL18857393 | 0.86 | QPCT (0.49) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL18857605 | 0.86 | QPCT (0.49) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL18862090 | 0.85 | CYP3A4 (0.50) | HRH3HRH4QPCTQPCTLCYP3A4 | |
| SCHEMBL18862060 | 0.80 | QPCT (0.46) | HRH3QPCTQPCTLCYP3A4CYP2D6 | |
| SCHEMBL17189358 | 0.76 | CYP3A4 (0.56) | HRH3HRH4CYP3A4 | |
| SCHEMBL12982022 | 0.76 | CYP3A4 (0.56) | HRH3HRH4CYP3A4 | |
| SCHEMBL18697423 | 0.76 | CYP3A4 (0.56) | HRH3HRH4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | disclosed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| US-20120088716-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2012-04-12 | — | — | US | disclosed |
| EP-2292272-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| EP-2289560-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-02 | — | — | EP | disclosed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088716-A1 | Polypeptide Protracting Tags | VIP, FGB, NPPA | HRH3 4426/4885HRH4 4117/4885QPCT 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.